Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Stephens Inc. AR

Stephens Inc. AR trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 7.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,025 shares of the pharmaceutical company’s stock after selling 320 shares during the period. Stephens Inc. AR’s holdings in Vertex Pharmaceuticals were worth $1,638,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Arlington Trust Co LLC grew its holdings in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares during the period. Fortitude Family Office LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $30,000. Baystate Wealth Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 25 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $33,000. Finally, Asset Dedication LLC raised its position in shares of Vertex Pharmaceuticals by 131.8% in the 3rd quarter. Asset Dedication LLC now owns 102 shares of the pharmaceutical company’s stock worth $35,000 after buying an additional 58 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on VRTX. Oppenheimer restated an “outperform” rating and set a $500.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. UBS Group dropped their target price on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a research note on Thursday, April 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. Three analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $438.62.

Get Our Latest Analysis on Vertex Pharmaceuticals

Insiders Place Their Bets

In other news, CEO Reshma Kewalramani sold 1,565 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $457.00, for a total value of $715,205.00. Following the completion of the sale, the chief executive officer now directly owns 121,374 shares in the company, valued at approximately $55,467,918. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Charles F. Wagner, Jr. sold 3,250 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $454.79, for a total value of $1,478,067.50. Following the transaction, the chief financial officer now directly owns 50,387 shares in the company, valued at approximately $22,915,503.73. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Reshma Kewalramani sold 1,565 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $457.00, for a total transaction of $715,205.00. Following the sale, the chief executive officer now directly owns 121,374 shares of the company’s stock, valued at approximately $55,467,918. The disclosure for this sale can be found here. Insiders have sold a total of 16,518 shares of company stock valued at $7,409,762 in the last quarter. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.5 %

NASDAQ VRTX opened at $483.04 on Monday. The company has a market capitalization of $124.65 billion, a price-to-earnings ratio of 31.35, a price-to-earnings-growth ratio of 2.48 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. Vertex Pharmaceuticals Incorporated has a 12 month low of $323.02 and a 12 month high of $486.42. The company’s fifty day moving average price is $423.13 and its two-hundred day moving average price is $414.33.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping the consensus estimate of $3.66 by $1.10. The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.67 earnings per share. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Stories

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.